IF 4.5 3区 医学 Q2 IMMUNOLOGY Vaccine Pub Date : 2024-09-18 DOI:10.1016/j.vaccine.2024.126375
{"title":"Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023–March 2024)","authors":"","doi":"10.1016/j.vaccine.2024.126375","DOIUrl":null,"url":null,"abstract":"<div><p>We assessed the impact of the 2023/2024 COVID-19 vaccination campaign in Italy by estimating the number of averted COVID-19 severe cases (i.e. COVID-19 associated hospitalisations or deaths) between October 2023 and March 2024, in those aged ≥60 years. We estimated that 565 (95 % CI: 497–625) cases, corresponding to 2.1 % (95 % CI: 1.8–2.3) of the expected cases without a vaccination campaign, were averted. We simulated three vaccination coverage scenarios: 50 %, 75 %, 90 % (versus the observed 10.7 %), finding that 9.7 % (95 % CI: 8.5–10.7); 14.5 % (95 % CI: 12.8–16.1); and 17.4 % (95 % CI: 15.3–19.3) of the expected cases would have been averted, respectively.</p></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0264410X24010570/pdfft?md5=d8bfb89ed048ed9c195a524ef76cd937&pid=1-s2.0-S0264410X24010570-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24010570","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

我们评估了2023/2024年意大利COVID-19疫苗接种活动的影响,估计了2023年10月至2024年3月期间在年龄≥60岁的人群中避免的COVID-19重症病例数(即与COVID-19相关的住院或死亡病例)。我们估计可避免 565 例病例(95 % CI:497-625),相当于未开展疫苗接种活动时预期病例的 2.1 %(95 % CI:1.8-2.3)。我们模拟了三种疫苗接种覆盖率情况:我们模拟了三种疫苗接种覆盖率情况:50%、75% 和 90%(相对于观察到的 10.7%),结果发现预期病例的 9.7%(95% CI:8.5-10.7)、14.5%(95% CI:12.8-16.1)和 17.4%(95% CI:15.3-19.3)将分别得以避免。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023–March 2024)

We assessed the impact of the 2023/2024 COVID-19 vaccination campaign in Italy by estimating the number of averted COVID-19 severe cases (i.e. COVID-19 associated hospitalisations or deaths) between October 2023 and March 2024, in those aged ≥60 years. We estimated that 565 (95 % CI: 497–625) cases, corresponding to 2.1 % (95 % CI: 1.8–2.3) of the expected cases without a vaccination campaign, were averted. We simulated three vaccination coverage scenarios: 50 %, 75 %, 90 % (versus the observed 10.7 %), finding that 9.7 % (95 % CI: 8.5–10.7); 14.5 % (95 % CI: 12.8–16.1); and 17.4 % (95 % CI: 15.3–19.3) of the expected cases would have been averted, respectively.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vaccine
Vaccine 医学-免疫学
CiteScore
8.70
自引率
5.50%
发文量
992
审稿时长
131 days
期刊介绍: Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.
期刊最新文献
Relative effectiveness of adjuvanted versus non-adjuvanted influenza vaccines in older adults with risk factors for influenza complications during the 2019–2020 U.S. influenza season Seasonal influenza vaccination: A global review of national policies in 194 WHO member states in 2022 Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023–March 2024) Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission T cell inducing vaccine against cytomegalovirus immediate early 1 (IE1) protein provides high level cross strain protection against congenital CMV
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1